Purpose：Bortezomib is the first proteasome inhibitor approved by FDA for multiple myeloma (a blood cancer). Reversible 26S proteasome inhibitor, a barrel shaped multi protein particle, exists in the nucleus and cytoplasm of all eukaryotic cells.
Structural formula:
Properties
Summary
Bortezomib is the first proteasome inhibitor approved by FDA for multiple myeloma (a blood cancer). Reversible 26S proteasome inhibitor, a barrel shaped multi protein particle, exists in the nucleus and cytoplasm of all eukaryotic cells. Targeting ubiquitin proteasome pathway.
Manufacturing
